Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 3Neuroblastoma 3Recurrence 2Neoplasms 2Melanoma 2Glioma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Medulloblastoma 1Lymphoma 1Lung Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Carcinosarcoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Advanced or Metastatic ER+ Breast Cancer 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

Paclitaxel 2Carboplatin 2rucaparib 1ribociclib 1rebastinib 1Fulvestrant 1DCC-2036 1Cisplatin 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinosarcoma × ribociclib × Clear all
NCT05252416 2025-11-28

(VELA) Study of BLU-222 in Advanced Solid Tumors

Blueprint Medicines Corporation

Phase 1 Terminated
50 enrolled
GastrointestinalGynecologicSarcoma

Adenocarcinoma Of Esophagus, Carcinosarcoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡